Scholars@Duke
Yiping He

Yiping He

Associate Professor in Pathology
Pathology

Selected Publications

Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.

Journal Article Prostate · March 2024 BACKGROUND: Prostate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration-resistant PCa (CRPC) often recurs and has limited treatment options. Our previous stu ... Full text Link to item Cite

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Journal Article Nat Commun · January 25, 2024 Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX, defining molecular alterations in IDH-mutant astrocytomas, have been implicated in dysfunctional immune signaling. ... Full text Link to item Cite

Heat shock factor 1 directly regulates transsulfuration pathway to promote prostate cancer proliferation and survival.

Journal Article Commun Biol · January 3, 2024 There are limited therapeutic options for patients with advanced prostate cancer (PCa). We previously found that heat shock factor 1 (HSF1) expression is increased in PCa and is an actionable target. In this manuscript, we identify that HSF1 regulates the ... Full text Open Access Link to item Cite

Gene expression analysis suggests immunosuppressive roles of endolysosomes in glioblastoma.

Journal Article PLoS One · 2024 Targeting endolysosomes is a strategy extensively pursued for treating cancers, including glioblastomas (GBMs), on the basis that the intact function of these subcellular organelles is key to tumor cell autophagy and survival. Through gene expression analy ... Full text Link to item Cite

Clemastine and hyperthermia enhance sensitization of osteosarcoma cells for apoptosis.

Journal Article Mol Cell Oncol · 2024 Clemastine is an antagonist of histamine H1 receptor may provide benefits in the treatment of osteosarcoma (OS). In the current study, we used hyperthermia approach to sensitize OS cells to clemastine-mediated cell death. Osteosarcoma U-2 OS and Saos-2 cel ... Full text Link to item Cite

Repurposing Clemastine to Target Glioblastoma Cell Stemness.

Journal Article Cancers (Basel) · September 18, 2023 Brain tumor-initiating cells (BTICs) and tumor cell plasticity promote glioblastoma (GBM) progression. Here, we demonstrate that clemastine, an over-the-counter drug for treating hay fever and allergy symptoms, effectively attenuated the stemness and suppr ... Full text Link to item Cite

Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.

Journal Article Neuro Oncol · September 5, 2023 BACKGROUND: Telomere maintenance mechanisms are required to enable the replicative immortality of malignant cells. While most cancers activate the enzyme telomerase, a subset of cancers uses telomerase-independent mechanisms termed alternative lengthening ... Full text Link to item Cite

Joint gene network construction by single-cell RNA sequencing data.

Journal Article Biometrics · June 2023 In contrast to differential gene expression analysis at the single-gene level, gene regulatory network (GRN) analysis depicts complex transcriptomic interactions among genes for better understandings of underlying genetic architectures of human diseases an ... Full text Link to item Cite

Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.

Journal Article J Pathol · May 2023 Neuroendocrine (NE) cells comprise ~1% of epithelial cells in benign prostate and prostatic adenocarcinoma (PCa). However, they become enriched in hormonally treated and castration-resistant PCa (CRPC). In addition, close to 20% of hormonally treated tumor ... Full text Link to item Cite

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

Journal Article bioRxiv · April 21, 2023 Stimulating the innate immune system has been explored as a therapeutic option for the treatment of gliomas. Inactivating mutations in ATRX , defining molecular alterations in IDH -mutant astrocytomas, have been implicated in dysfunctional immune signaling ... Full text Link to item Cite

Rewiring of the N-Glycome with prostate cancer progression and therapy resistance.

Journal Article NPJ Precis Oncol · February 24, 2023 An understanding of the molecular features associated with prostate cancer progression (PCa) and resistance to hormonal therapy is crucial for the identification of new targets that can be utilized to treat advanced disease and prolong patient survival. Th ... Full text Link to item Cite

Purine Synthesis Inhibitor L-Alanosine Impairs Mitochondrial Function and Stemness of Brain Tumor Initiating Cells.

Journal Article Biomedicines · March 23, 2022 Glioblastoma (GBM) is a lethal brain cancer exhibiting high levels of drug resistance, a feature partially imparted by tumor cell stemness. Recent work shows that homozygous MTAP deletion, a genetic alteration occurring in about half of all GBMs, promotes ... Full text Link to item Cite

MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization.

Journal Article Sci Rep · March 9, 2022 Glioblastoma (GBM) is a lethal brain cancer known for its potent immunosuppressive effects. Loss of Methylthioadenosine Phosphorylase (MTAP) expression, via gene deletion or epigenetic silencing, is one of the most common alterations in GBM. Here we show t ... Full text Link to item Cite

Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.

Journal Article Oncogene · February 2022 Advanced and aggressive prostate cancer (PCa) depends on glutamine for survival and proliferation. We have previously shown that inhibition of glutaminase 1, which catalyzes the rate-limiting step of glutamine catabolism, achieves significant therapeutic e ... Full text Link to item Cite

Epigenetic Regulation of Fanconi Anemia Genes Implicates PRMT5 Blockage as a Strategy for Tumor Chemosensitization.

Journal Article Mol Cancer Res · December 2021 Strengthened DNA repair pathways in tumor cells contribute to the development of resistance to DNA-damaging agents. Consequently, targeting proteins in these pathways is a promising strategy for tumor chemosensitization. Here, we show that the expression o ... Full text Link to item Cite

TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.

Journal Article Acta Neuropathol Commun · November 3, 2021 Diffuse intrinsic pontine gliomas (DIPGs) are high-grade tumors of the brainstem that often occur in children, with a median overall survival of less than one year. Given the fact that DIPGs are resistant to chemotherapy and are not amenable to surgical re ... Full text Link to item Cite

BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS

Conference Neuro-Oncology · June 1, 2021 AbstractMyc plays a central role in tumorigenesis by orchestrating the expression of genes essential to numerous cellular processes. While it is well established that Myc functions by binding to its target g ... Full text Cite

A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer.

Journal Article Proc Natl Acad Sci U S A · March 30, 2021 Cellular metabolism in cancer is significantly altered to support the uncontrolled tumor growth. How metabolic alterations contribute to hormonal therapy resistance and disease progression in prostate cancer (PCa) remains poorly understood. Here we report ... Full text Link to item Cite

Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer.

Journal Article Int J Biol Markers · March 2021 BACKGROUND: BRCA1 and BRCA2 have been well studied for their roles in tumorigeneis, plus cancer diagnosis and treatment, but their prognostic value in colon cancer, especially for early-stage cancer, has not been fully illuminated. This study examined the ... Full text Link to item Cite

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.

Journal Article Nat Commun · January 13, 2021 Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunother ... Full text Open Access Link to item Cite

Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.

Journal Article Mol Cancer Res · July 2020 Diffuse intrinsic pontine glioma (DIPG) is an invariably fatal brain tumor occurring predominantly in children. Up to 90% of pediatric DIPGs harbor a somatic heterozygous mutation resulting in the replacement of lysine 27 with methionine (K27M) in genes en ... Full text Link to item Cite

The integrated genomic and epigenomic landscape of brainstem glioma.

Journal Article Nat Commun · June 17, 2020 Brainstem gliomas are a heterogeneous group of tumors that encompass both benign tumors cured with surgical resection and highly lethal cancers with no efficacious therapies. We perform a comprehensive study incorporating epigenetic and genomic analyses on ... Full text Link to item Cite

Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer.

Journal Article Sci Transl Med · December 4, 2019 Hormonal therapy targeting androgen receptor (AR) is initially effective to treat prostate cancer (PCa), but it eventually fails. It has been hypothesized that cellular heterogeneity of PCa, consisting of AR+ luminal tumor cells and AR- neuroendocrine (NE) ... Full text Link to item Cite

MTAP LOSS COMPROMISES DNA DAMAGE RESPONSE IN GBM CELLS

Conference NEURO-ONCOLOGY · November 1, 2019 Link to item Cite

CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.

Journal Article Mol Cancer Res · October 2019 Mutations in isocitrate dehydrogenases 1 and 2 (IDH) occur in the majority of World Health Organization grade II and III gliomas. IDH1/2 active site mutations confer a neomorphic enzyme activity producing the oncometabolite D-2-hydroxyglutarate (D-2HG), wh ... Full text Link to item Cite

A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.

Journal Article Cell Rep · September 17, 2019 H2AX safeguards genomic stability in a dose-dependent manner; however, mechanisms governing its proteostasis are poorly understood. Here, we identify a PRMT5-RNF168-SMURF2 cascade that regulates H2AX proteostasis. We show that PRMT5 sustains the expression ... Full text Link to item Cite

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Journal Article Cancer Res · July 1, 2019 Homozygous deletion of methylthioadenosine phosphorylase (MTAP) is one of the most frequent genetic alterations in glioblastoma (GBM), but its pathologic consequences remain unclear. In this study, we report that loss of MTAP results in profound epigenetic ... Full text Link to item Cite

Hereditary brain tumor with a homozygous germline mutation in PMS2: pedigree analysis and prenatal screening in a family with constitutional mismatch repair deficiency (CMMRD) syndrome.

Journal Article Fam Cancer · April 2019 Precise genetic counseling and prenatal diagnosis are often hindered by incomplete penetrance of risk variance and complex patterns of inheritance. Here, we performed a clinical and genetic study of a five-generation Pakistani family with a history of mult ... Full text Link to item Cite

Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.

Journal Article Neuro Oncol · March 18, 2019 BACKGROUND: Mutations in telomerase reverse transcriptase promoter (TERTp) and isocitrate dehydrogenase 1 and 2 (IDH) offer objective markers to assist in classifying diffuse gliomas into genetic subgroups. However, traditional mutation detection technique ... Full text Link to item Cite

Mutant allele quantification reveals a genetic basis for TP53 mutation-driven castration resistance in prostate cancer cells.

Journal Article Sci Rep · August 21, 2018 The concept that human cancer is in essence a genetic disease driven by gene mutations has been well established, yet its utilization in functional studies of cancer genes has not been fully explored. Here, we describe a simple genetics-based approach that ... Full text Link to item Cite

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.

Journal Article Nat Commun · May 25, 2018 The majority of glioblastomas can be classified into molecular subgroups based on mutations in the TERT promoter (TERTp) and isocitrate dehydrogenase 1 or 2 (IDH). These molecular subgroups utilize distinct genetic mechanisms of telomere maintenance, eithe ... Full text Link to item Cite

Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.

Journal Article Cancer Res · January 1, 2018 Hotspot mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in a number of human cancers and confer a neomorphic enzyme activity that catalyzes the conversion of α-ketoglutarate (αKG) to the oncometabolite D-(2)-hydroxyglutarate (D2HG). In malign ... Full text Link to item Cite

Cic Loss Promotes Gliomagenesis via Aberrant Neural Stem Cell Proliferation and Differentiation.

Journal Article Cancer Res · November 15, 2017 Inactivating mutations in the transcriptional repression factor Capicua (CIC) occur in approximately 50% of human oligodendrogliomas, but mechanistic links to pathogenesis are unclear. To address this question, we generated Cic-deficient mice and human oli ... Full text Link to item Cite

Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.

Journal Article Oncotarget · September 29, 2017 Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor, with a median survival of less than one year. Due to enormous difficulties in the acquisition of DIPG specimens and the sophisticated technique required to perform brainstem orthotopic i ... Full text Link to item Cite

Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors.

Journal Article Oncotarget · July 28, 2017 Diffuse intrinsic pontine glioma (DIPG) is a devastating brain tumor, with a median survival of less than one year. Due to enormous difficulties in the acquisition of DIPG specimens and the sophisticated technique required to perform brainstem orthotopic i ... Full text Link to item Cite

Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.

Journal Article Mol Cancer Res · May 2017 IDH1 mutations occur in the majority of low-grade gliomas and lead to the production of the oncometabolite, D-2-hydroxyglutarate (D-2HG). To understand the effects of tumor-associated mutant IDH1 (IDH1-R132H) on both the neural stem cell (NSC) population a ... Full text Link to item Cite

Preclinical Immunotherapeutic Animal Models for Brain Tumors

Chapter · March 2, 2017 Glioblastoma (GBM) is the most malignant primary brain tumor in adults. Even with the current standard of care therapy (i.e., surgery, radiotherapy, and chemotherapy), GBM has a poor prognosis. Innovative immunotherapeutic approaches, which engage a patien ... Full text Cite

Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.

Journal Article Clin Cancer Res · January 1, 2017 A new 30-gene signature has been described that separates prostate cancers of Gleason score ≤6 from those of Gleason score ≥8. It provides independent prognostic information for prostate cancers of intermediate risk (Gleason score of 7), which has the pote ... Full text Open Access Link to item Cite

Prevalence of deleterious ATM germline mutations in gastric cancer patients.

Journal Article Oncotarget · December 1, 2015 Besides CDH1, few hereditary gastric cancer predisposition genes have been previously reported. In this study, we discovered two germline ATM mutations (p.Y1203fs and p.N1223S) in a Chinese family with a history of gastric cancer by screening 83 cancer sus ... Full text Link to item Cite

Abstract 63: Driving brain tumorigenesis: Generation of a mutant IDH1 mouse model of progressive glioma

Conference Cancer Research · October 1, 2014 AbstractDespite decades worth of research, glioblastoma remains one of the most lethal cancers. The identification of IDH1 as a major cancer gene in glioblastoma provides a great opportunity for improving ou ... Full text Cite

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.

Journal Article Nat Genet · July 2014 Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect. To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic g ... Full text Link to item Cite

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.

Journal Article Oncotarget · March 30, 2014 Frequent mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) and the promoter of telomerase reverse transcriptase (TERT) represent two significant discoveries in glioma genomics. Understanding the degree to which these two mutations co-occur or o ... Full text Open Access Link to item Cite

The genetic landscape of anaplastic astrocytoma.

Journal Article Oncotarget · March 30, 2014 Anaplastic astrocytoma WHO grade III (A3) is a lethal brain tumor that often occurs in middle aged patients. Clinically, it is challenging to distinguish A3 from glioblastoma multiforme (GBM) WHO grade IV. To reveal the genetic landscape of this tumor type ... Full text Link to item Cite

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas

Journal Article Nature Genetics · January 1, 2014 Gliomas arising in the brainstem and thalamus are devastating tumors that are difficult to surgically resect. To determine the genetic and epigenetic landscape of these tumors, we performed exomic sequencing of 14 brainstem gliomas (BSGs) and 12 thalamic g ... Full text Cite

Chromatin accessibility mapping identifies mediators of basal transcription and retinoid-induced repression of OTX2 in medulloblastoma.

Journal Article PLoS One · 2014 Despite an emerging understanding of the genetic alterations giving rise to various tumors, the mechanisms whereby most oncogenes are overexpressed remain unclear. Here we have utilized an integrated approach of genomewide regulatory element mapping via DN ... Full text Open Access Link to item Cite

KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.

Journal Article Oncotarget · November 2013 KMT2D (lysine (K)-specific methyltransferase 2D), formerly named MLL2 (myeloid/lymphoid or mixed-lineage leukemia 2, also known as ALR/MLL4), is a histone methyltransferase that plays an important role in regulating gene transcription. In particular, it ta ... Full text Link to item Cite

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Journal Article Proc Natl Acad Sci U S A · April 9, 2013 Malignant cells, like all actively growing cells, must maintain their telomeres, but genetic mechanisms responsible for telomere maintenance in tumors have only recently been discovered. In particular, mutations of the telomere binding proteins alpha thala ... Full text Link to item Cite

Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.

Journal Article Cancer Res · January 15, 2013 Point mutations at Arg132 of the cytoplasmic NADP(+)-dependent isocitrate dehydrogenase 1 (IDH1) occur frequently in gliomas and result in a gain of function to produce the "oncometabolite" D-2-hydroxyglutarate (D-2HG). The mutated IDH1 allele is usually a ... Full text Open Access Link to item Cite

Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways.

Journal Article Proc Natl Acad Sci U S A · October 23, 2012 Myeloid/lymphoid or mixed-lineage leukemia (MLL)-family genes encode histone lysine methyltransferases that play important roles in epigenetic regulation of gene transcription. MLL genes are frequently mutated in human cancers. Unlike MLL1, MLL2 (also know ... Full text Link to item Cite

Mutant IDH1 is required for IDH1 mutated tumor cell growth.

Journal Article Oncotarget · August 2012 Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protei ... Full text Open Access Link to item Cite

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.

Journal Article Oncotarget · July 2012 Mutations in the critical chromatin modifier ATRX and mutations in CIC and FUBP1, which are potent regulators of cell growth, have been discovered in specific subtypes of gliomas, the most common type of primary malignant brain tumors. However, the frequen ... Full text Open Access Link to item Cite

Aberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cells.

Journal Article PLoS One · 2012 Dysregulation of Otx2 is a hallmark of the pediatric brain tumor medulloblastoma, yet its functional significance in the establishment of these tumors is unknown. Here we have sought to determine the functional consequences of Otx2 overexpression in the mo ... Full text Link to item Cite

Altered telomeres in tumors with ATRX and DAXX mutations.

Journal Article Science · July 22, 2011 The proteins encoded by ATRX and DAXX participate in chromatin remodeling at telomeres and other genomic sites. Because inactivating mutations of these genes are common in human pancreatic neuroendocrine tumors (PanNETs), we examined the telomere status of ... Full text Link to item Cite

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.

Journal Article Proc Natl Acad Sci U S A · February 22, 2011 Point mutations of the NADP(+)-dependent isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and IDH2 gain the ability to produce the metabolite (R)-2-hydroxyglutarate (2HG), but the downstream e ... Full text Link to item Cite

The genetic landscape of the childhood cancer medulloblastoma.

Journal Article Science · January 28, 2011 Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high-density microarrays and sequenced all known protein-coding genes and micro ... Full text Link to item Cite

Heteroplasmic mitochondrial DNA mutations in normal and tumour cells.

Journal Article Nature · March 25, 2010 The presence of hundreds of copies of mitochondrial DNA (mtDNA) in each human cell poses a challenge for the complete characterization of mtDNA genomes by conventional sequencing technologies. Here we describe digital sequencing of mtDNA genomes with the u ... Full text Link to item Cite

Sensitive digital quantification of DNA methylation in clinical samples.

Journal Article Nat Biotechnol · September 2009 Analysis of abnormally methylated genes is increasingly important in basic research and in the development of cancer biomarkers. We have developed methyl-BEAMing technology to enable absolute quantification of the number of methylated molecules in a sample ... Full text Link to item Cite

Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A.

Journal Article Genes Dev · July 15, 2009 Precise control of the timing and magnitude of Notch signaling is essential for the normal development of many tissues, but the feedback loops that regulate Notch are poorly understood. Developing T cells provide an excellent context to address this issue. ... Full text Link to item Cite

The antisense transcriptomes of human cells.

Journal Article Science · December 19, 2008 Transcription in mammalian cells can be assessed at a genome-wide level, but it has been difficult to reliably determine whether individual transcripts are derived from the plus or minus strands of chromosomes. This distinction can be critical for understa ... Full text Link to item Cite

Constitutive Notch signalling promotes CD4 CD8 thymocyte differentiation in the absence of the pre-TCR complex, by mimicking pre-TCR signals.

Journal Article Int Immunol · December 2007 Notch1 signalling is essential for the commitment of multipotent lymphocyte precursors towards the alphabeta T-cell lineage and plays an important role in regulating beta-selection in CD4(-)CD8(-) double-negative (DN) thymocytes. However, the role played b ... Full text Link to item Cite

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.

Journal Article Blood · November 15, 2007 Gene expression profiling of acute myeloid leukemia (AML) allows the discovery of previously unrecognized molecular entities. Here, we identified a specific subgroup of AML, defined by an expression profile resembling that of AMLs with mutations in the mye ... Full text Link to item Cite

Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia.

Journal Article Cancer Cell · November 2006 Tribbles homolog 2 (Trib2) was identified as a downregulated transcript in leukemic cells undergoing growth arrest. To investigate the effects of Trib2 in hematopoietic progenitors, mice were reconstituted with hematopoietic stem cells retrovirally express ... Full text Link to item Cite

The colorectal microRNAome.

Journal Article Proc Natl Acad Sci U S A · March 7, 2006 MicroRNAs (miRNAs) are a class of small noncoding RNAs that have important regulatory roles in multicellular organisms. The public miRNA database contains 321 human miRNA sequences, 234 of which have been experimentally verified. To explore the possibility ... Full text Link to item Cite

Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies.

Journal Article Blood · December 1, 2005 Although Notch receptor expression on malignant B cells is widespread, the effect of Notch signaling in these cells is poorly understood. To investigate Notch signaling in B-cell malignancy, we assayed the effect of Notch activation in multiple murine and ... Full text Link to item Cite

Detection and quantification of mutations in the plasma of patients with colorectal tumors.

Journal Article Proc Natl Acad Sci U S A · November 8, 2005 The early detection of cancers through analysis of circulating DNA could have a substantial impact on morbidity and mortality. To achieve this goal, it is essential to determine the number of mutant molecules present in the circulation of cancer patients a ... Full text Link to item Cite

Notch 1 signaling regulates peripheral T cell activation.

Journal Article Immunity · April 2004 Notch signaling has been identified as an important regulator of leukocyte differentiation and thymic maturation. Less is known about the role of Notch signaling in regulating mature T cells. We examined the role of Notch 1 in regulating peripheral T cell ... Full text Link to item Cite

From the yolk sac to the spleen: New roles for Notch in regulating hematopoiesis.

Journal Article Immunity · May 2003 Although Notch receptors are widely expressed during hematopoiesis, their roles outside of the T cell lineage are not well characterized. Two reports in this issue of Immunity show that Notch1 and Notch2, respectively, are required to generate the earliest ... Full text Link to item Cite

Notch signalling in B cells.

Journal Article Semin Cell Dev Biol · April 2003 Notch signalling is likely to regulate multiple aspects of lymphoid development and function. During T cell development, Notch signalling is required for commitment of the earliest progenitor, and may also function during other developmental stages. T cell ... Full text Link to item Cite

The biology of chronic myelogenous leukemia:mouse models and cell adhesion.

Journal Article Oncogene · December 9, 2002 Chronic myelogenous leukemia (CML) is a biphasic neoplasm of the bone marrow that is precipitated by the Philadelphia chromosome, a t(9;22) balanced translocation that encodes a constitutively activated nonreceptor tyrosine kinase termed P210(BCR-ABL). Thi ... Full text Link to item Cite

The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.

Journal Article Blood · April 15, 2002 The bcr/abl fusion in chronic myelogenous leukemia (CML) creates a chimeric tyrosine kinase with dramatically different properties than intact c-abl. In P210 bcr/abl, the bcr portion includes a coiled-coil oligomerization domain (amino acids 1-63) and a gr ... Full text Link to item Cite

Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1.

Journal Article Immunity · February 2002 Notch1 signaling drives T cell development at the expense of B cell development from a common precursor, an effect that is dependent on a C-terminal Notch1 transcriptional activation domain. The function of Deltex1, initially identified as a positive modul ... Full text Link to item Cite